Micro-RNAs in cancer: novel origins and sequence variation

Feng Yu

M.Sc., B.Sc.

This thesis is submitted in fulfilment of the requirements for the Doctor of Philosophy

School of Medicine
The University of Adelaide
Adelaide SA, Australia
March 2016
# Table of Contents

Table of Contents ............................................................................................................. I

Overview ............................................................................................................................. III

Publications ........................................................................................................................ VI

Acknowledgements ........................................................................................................... VII

Declaration ........................................................................................................................ IX

Chapter 1 ............................................................................................................................. 1

1. **THE INTERACTION BETWEEN P53 AND NON-CODING RNAs FROM NOVEL SOURCES** ........................................... 2
   1.1. The p53 pathway – a key tumour suppressive pathway ............................................. 2
   1.2. Non-coding RNAs -- a new route by p53 to regulate the transcriptome .................. 4
       1.2.1. miRNAs are vital cancer regulators ................................................................. 6
       1.2.2. MicroRNAs directly regulated by p53 ............................................................ 7
       1.2.3. p53 regulates the transcription of miRNAs ..................................................... 9
       1.2.4. p53 regulates miRNA maturation ................................................................. 11
       1.2.5. The reciprocal interaction of p53 and its target miRNAs ............................... 12
       1.2.6. Clinical implications of p53-regulated miRNAs ............................................. 12
       1.2.7. p53 regulation of small non-coding RNAs processed by RNA polymerase I and II ........... 14
       1.2.8. Potential sources of novel miRNAs under p53 regulation .............................. 15
   1.3. **Post-transcriptional roles of long non-coding RNAs (lncRNAs) in the p53 downstream network** .................................... 17
       1.3.1. Introduction to lncRNA .................................................................................. 17
       1.3.2. Post-transcriptional regulatory roles of lncRNAs ............................................ 18
       1.3.3. Regulatory roles of lncRNAs directly targeted by p53 ...................................... 20
   1.4. Conclusion ............................................................................................................. 23

2. **ISOMiRS – NATURALLY EXISTING ISOFORMS OF miRNAs** ........................................... 24
   2.1. The maturation of miRNA and its heterogeneity .................................................... 24
       2.1.1. The existence of 5' and 3' isomiRs ............................................................... 28
   2.2. Sources of miRNA heterogeneity ....................................................................... 29
       2.2.1. 5' and 3' heterogeneity derived from the biogenesis of isomiRs ................. 30
       2.2.2. 3' heterogeneity derived from trimming and nucleotidyl transferring .......... 31
       2.2.3. Heterogeneity derived from RNA editing ................................................... 32
   2.3. Functional impacts of miRNA heterogeneity ..................................................... 34
       2.3.1. Alteration in target recognition ................................................................. 35
       2.3.2. Alteration in AGO loading ........................................................................... 36
       2.3.3. Alteration in miRNA stability ....................................................................... 37
   2.4. Discussion ........................................................................................................... 38
3. SUMMARY OF THE CHAPTER ........................................................................... 39
RESEARCH ............................................................................................................. 41
Chapter 2 .................................................................................................................. 69
PRELUDE .................................................................................................................. 70
ABSTRACT ............................................................................................................... 74
INTRODUCTION ....................................................................................................... 75
RESULTS ................................................................................................................... 77
  Identification of p53 regulated snoRNAs ............................................................... 77
  p53 repressed snoRNAs are processed into miRNAs ............................................ 85
  sno-miR-28 functions as a miRNA ...................................................................... 92
  sno-miR-28 alters p53 protein stability through TAF9B ...................................... 97
  sno-miR-28 is upregulated in breast tumours and promotes breast cell proliferation ............................................................................................................ 101
DISCUSSION .......................................................................................................... 104
  snoRNAs are processed into miRNAs ................................................................. 104
  sno-miR-28 is a novel member of the p53 regulatory network ............................... 106
  sno-miR-28 is overexpressed in breast tumour samples and plays an oncogenic role in breast cells ........................................................................................................... 107
MATERIALS AND METHODS ............................................................................... 108
ACKNOWLEDGEMENTS .......................................................................................... 124
REFERENCES ......................................................................................................... 125
Chapter 3 .................................................................................................................. 136
PRELUDE .................................................................................................................. 137
ABSTRACT ............................................................................................................... 142
INTRODUCTION ....................................................................................................... 143
RESULTS ................................................................................................................... 147
  Endogenous expression of miR-222 isoforms ..................................................... 147
  miR-222 isoforms significantly alter cell morphology ........................................ 148
  All four miR-222 species inhibit cell proliferation ............................................. 152
  Longer miR-222 isoforms are associated with increased apoptotic activity ........ 157
  The differential apoptotic activity of longer 222 isomiRs is not attributable to interferon responses .............................................................................................................. 160
  PIK3R3 (p55) is involved in miR-222CUCU-induced apoptosis ............................. 163
DISCUSSION .......................................................................................................... 171
MATERIALS AND METHODS ............................................................................... 175
REFERENCES ......................................................................................................... 187
Conclusion ............................................................................................................... 198
REFERENCES ......................................................................................................... 203
Overview

Non-coding RNAs have become a hot topic of cancer research in recent decades, with miRNAs being probably the most active area of research. However, the functions of short non-coding RNA (ncRNA) fragments commonly existing in cells remains less understood. Herein we explore the novel ncRNAs which play a role in cancer progression.

The first part of the thesis focuses on miRNAs processed from novel sources that have a role in p53 regulation. p53 is a master tumour repressor that participates in vast regulatory networks, including feedback loops involving microRNAs (miRNAs) that regulate p53 and that themselves are direct p53 transcriptional targets. A group of polycistronic miRNA-like non-coding RNAs is derived from small nucleolar RNAs (sno-miRNAs) that are transcriptionally repressed by p53 through their host gene, SNHG1. Among them, sno-miR-28 is the most abundant sno-miRNA bound to the AGO (Argonaute) proteins and it directly targets TAF9B, thereby de-stabilizing p53. Therefore, a positive a regulatory loop was observed comprising p53, SNHG1, sno-miR-28 and TAF9B, which influences p53 stability and downstream p53-regulated pathways. In addition, SNHG1, SNORD28 and sno-miR-28 are all significantly upregulated in breast tumours and the overexpression of sno-miR-28 promotes breast
epithelial cell proliferation and colony formation. This research has broadened our knowledge of the crosstalk between small non-coding RNA pathways and p53 regulation.

The second part of the thesis investigates naturally existing isoforms of miR-222 that play pro-apoptotic roles. Alternative processing at the 3' end of miRNAs has been broadly observed, producing variable lengths of miRNA mature forms. Deep-sequencing of various tissues and tumours, combined with sequencing of AGO-bound miRNAs from cell lines, indicates a variable proportion of endogenous miR-222 that is extended by one to five nucleotides at the 3' end. We demonstrated that the 3' heterogeneity of miR-222 possesses dramatic implications for the phenotype of miR-222 transfected cells, with longer isoforms driving apoptosis in addition to the proliferation inhibition bestowed by both the short (canonical) and longer forms. Further investigation revealed intrinsic apoptotic events exhibiting a positive correlation to the length of miR-222 isoforms, but not the specific 3' sequence. However, the apoptosis failed to be correlated to interferon immunoresponse, and the longer miR-222 isoform exhibits identical targeting activity as the canonical miR-222.

Widespread disruption of the expression of key PI3K-AKT components was observed upon miR-222CUCU transfection. A PI3K regulatory subunit, PIK3R3, was of particular interest, as siPIK3R3 phenocopied miR-222CUCU in terms of
apoptotic effects and inhibition of PI3K-AKT gene expression. Given the high prevalence of 3’ variance in many other miRNAs, the functional impact of miR-222 isoforms reveals another layer of miRNA regulation that has implications for cancer therapy.

Taken together, the existence of miRNAs processed from novel sources and isomiRs has added to the complexity of our knowledge about miRNA regulation. These areas are much less explored than conventional miRNA processing and regulation, but their profound molecular biological and physiological implications suggest an unexplored layer of miRNA biology and may shed light to the contemporary research of cancer progression.
Publications

Original Research Papers


Presentations

- Poster: Naturally existing isoforms of miR-222 play distinct pro-apoptotic roles. The 7th Barossa Meeting on cell signalling in cancer biology and therapy, 18-21 Nov. 2015

- Poster: Naturally existing isoforms of miR-222 play distinct pro-apoptotic roles. ASMR SA Annual Scientific Meeting, 3 June 2015.

Acknowledgements

A major research projects such as this would not have been completed without the collaboration of many different people, who have made this work possible. I would like to extend my gratitude and appreciation to the following:

Firstly, I sincerely wish to thank my supervisors, Dr Cameron Bracken and Dr Paul Neilsen. With their daily encouragement and continuous support, I was led into the world of scientific research. Their unsurpassed knowledge and unwavering enthusiasm for science constantly inspired me to work harder and think more. I doubt that I will be able to convey my appreciation fully, but I own Dr Cameron Bracken and Dr Paul Neilsen my eternal gratitude and could not have asked for a better mentor to guide me through this long journey.

I am extremely grateful for my supervisors Prof David Callen and Prof Gregory Goodall. They were the ones who pointed me the direction of my study and offered me a perfect environment to conduct my scientific research. Thank you for all your support and academic guidance over the years.
I would like to thank the bioinformatics people, Katherine Pillman, John Toubia, David Lawrence and Anna Tsykin, who have contributed valuable parts in our research. Without them, we would have never been able to expand our research to such a depth.

I would like to thank all my colleagues in the laboratories, in particular Alaknanda Alaknanda, who has collaborated with me intensively and offered indispensable help in flow cytometry and cell experiments. In particular, thank you to Renee Schulz, our former laboratory manager with huge experience, who supported me to establish my laboratory skills and helped me greatly for the experimental techniques in my first two years.

Special thanks to the University of Adelaide for providing me with a scholarship and comfortable research environment during my work towards the thesis.

Last, I dedicate my thesis to my family, in particular my wonderful partner Qian Yu, for his patience and unconditional support. He helped me both emotionally and physically in the daily life throughout the last two years.
Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.
I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Feng Yu

29 Mar 2016